Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totalling 191,300 shares, a decline of 44.8% from the March 31st total of 346,800 shares. Based on an average daily volume of 59,500 shares, the days-to-cover ratio is presently 3.2 days. Approximately 1.2% of the shares of the stock are short sold.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "buy" rating and set a $7.00 price objective on shares of Immix Biopharma in a research note on Monday, February 10th.
Get Our Latest Stock Analysis on Immix Biopharma
Institutional Investors Weigh In On Immix Biopharma
A number of hedge funds have recently made changes to their positions in the stock. SBI Securities Co. Ltd. bought a new stake in Immix Biopharma during the 4th quarter worth $38,000. Jane Street Group LLC bought a new stake in shares of Immix Biopharma in the fourth quarter worth $39,000. FNY Investment Advisers LLC acquired a new position in Immix Biopharma during the 4th quarter worth about $63,000. Finally, Geode Capital Management LLC raised its position in shares of Immix Biopharma by 5.6% during the third quarter. Geode Capital Management LLC now owns 150,082 shares of the company's stock worth $224,000 after acquiring an additional 7,954 shares during the last quarter. 11.26% of the stock is currently owned by institutional investors and hedge funds.
Immix Biopharma Price Performance
NASDAQ:IMMX traded up $0.06 during mid-day trading on Friday, reaching $2.10. The stock had a trading volume of 59,636 shares, compared to its average volume of 125,481. Immix Biopharma has a 12 month low of $1.26 and a 12 month high of $2.71. The stock has a market capitalization of $58.22 million, a PE ratio of -2.47 and a beta of 0.30. The stock has a 50-day simple moving average of $1.70 and a two-hundred day simple moving average of $1.87.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.09. Equities analysts expect that Immix Biopharma will post -0.87 EPS for the current year.
About Immix Biopharma
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Featured Articles
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.